Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities
Fuente:
arXiv
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Preprint |
| Veröffentlicht: |
2026
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866908882263080960 |
|---|---|
| author | Sehgal, Neil K. R. Tronieri, Jena Shaw Ungar, Lyle Guntuku, Sharath Chandra |
| author_facet | Sehgal, Neil K. R. Tronieri, Jena Shaw Ungar, Lyle Guntuku, Sharath Chandra |
| contents | Social media can reveal patient experiences with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that extend beyond clinical trial data. We analyzed 410,198 Reddit posts (May 2019-June 2025) mentioning semaglutide or tirzepatide. A total of 67,008 users self-reported using these medications, and 43.5% described at least one side effect. Gastrointestinal symptoms predominated, including nausea (36.9%), fatigue (16.7%), vomiting (16.3%), constipation (15.3%), and diarrhea (12.6%). Notably, reproductive symptoms (e.g., menstrual irregularities) and temperature-related complaints (e.g., chills, hot flashes) emerged as unrecognized potential effects. These findings highlight patient concerns not well captured in current labeling or trials. Large-scale social media analysis can complement traditional pharmacovigilance by detecting emerging safety signals and expanding understanding of the real-world safety profile of GLP-1 RAs. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2603_12341 |
| institution | arXiv |
| publishDate | 2026 |
| record_format | arxiv |
| spellingShingle | Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities Sehgal, Neil K. R. Tronieri, Jena Shaw Ungar, Lyle Guntuku, Sharath Chandra Social and Information Networks Quantitative Methods Social media can reveal patient experiences with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that extend beyond clinical trial data. We analyzed 410,198 Reddit posts (May 2019-June 2025) mentioning semaglutide or tirzepatide. A total of 67,008 users self-reported using these medications, and 43.5% described at least one side effect. Gastrointestinal symptoms predominated, including nausea (36.9%), fatigue (16.7%), vomiting (16.3%), constipation (15.3%), and diarrhea (12.6%). Notably, reproductive symptoms (e.g., menstrual irregularities) and temperature-related complaints (e.g., chills, hot flashes) emerged as unrecognized potential effects. These findings highlight patient concerns not well captured in current labeling or trials. Large-scale social media analysis can complement traditional pharmacovigilance by detecting emerging safety signals and expanding understanding of the real-world safety profile of GLP-1 RAs. |
| title | Self-Reported Side Effects of Semaglutide and Tirzepatide in Online Communities |
| topic | Social and Information Networks Quantitative Methods |
| url | https://arxiv.org/abs/2603.12341 |